发表后同行评议以及确定COVID-19试验的方法学和报告问题:一项定性研究

IF 7.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL BMJ Evidence-Based Medicine Pub Date : 2025-07-21 DOI:10.1136/bmjebm-2024-113068
Mauricia Davidson, Christoffer Bruun Korfitsen, Carolina Riveros, Anna Chaimani, Isabelle Boutron
{"title":"发表后同行评议以及确定COVID-19试验的方法学和报告问题:一项定性研究","authors":"Mauricia Davidson, Christoffer Bruun Korfitsen, Carolina Riveros, Anna Chaimani, Isabelle Boutron","doi":"10.1136/bmjebm-2024-113068","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to determine to what extent systematic reviewers and post-preprint and post-publication peer review identified methodological and reporting issues in COVID-19 trials that could be easily resolved by the authors.</p><p><strong>Design: </strong>Qualitative study.</p><p><strong>Data sources: </strong>COVID-NMA living systematic review (covid-nma.com), PubPeer, medRxiv, Research Square, SSRN.</p><p><strong>Methods: </strong>We considered randomised controlled trials (RCTs) in COVID-NMA that evaluated pharmacological treatments for COVID-19 and retrieved systematic reviewers' assessments of the risk of bias and outcome reporting bias. We also searched for commentary data on PubPeer and preprint servers up to 6 November 2023. We employed qualitative content analysis to develop themes and domains of methodological and reporting issues identified by commenters.</p><p><strong>Results: </strong>We identified 500 eligible RCTs. Systematic reviewers identified methodological and reporting issues in 446 (89%) RCTs. In 391 (78%) RCTs, the issues could be easily resolved by the trial authors; issues included incomplete reporting (49%), selection of the reported results (52%) and no access to the pre-specified plan (25%). Alternatively, 74 (15%) RCTs had received at least one comment on PubPeer or preprint servers, totalling 348 comments. In 46 (9%) RCTs, the issues identified by post-preprint and post-publication peer review comments could be easily resolved by the trial authors; the issues were related to incomplete reporting (6%), errors (5%), statistical analysis (3%), inconsistent reporting of methods and analyses (2%), spin (2%), selection of the reported results (1%) and no access to the raw data/pre-specified plan (1%).</p><p><strong>Conclusions: </strong>Without changing their process, systematic reviewers identified issues in most RCTs that could be easily resolved by the trial authors; however, the lack of an established author feedback mechanism represents a wasted opportunity for facilitating improvement and enhancing the overall manuscript quality. On the other hand, despite the existing feedback loop to authors present in post-publication peer review, it demonstrated limited effectiveness in identifying methodological and reporting issues.</p>","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"233-240"},"PeriodicalIF":7.6000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320597/pdf/","citationCount":"0","resultStr":"{\"title\":\"Post-publication peer review and the identification of methodological and reporting issues in COVID-19 trials: a qualitative study.\",\"authors\":\"Mauricia Davidson, Christoffer Bruun Korfitsen, Carolina Riveros, Anna Chaimani, Isabelle Boutron\",\"doi\":\"10.1136/bmjebm-2024-113068\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>We aimed to determine to what extent systematic reviewers and post-preprint and post-publication peer review identified methodological and reporting issues in COVID-19 trials that could be easily resolved by the authors.</p><p><strong>Design: </strong>Qualitative study.</p><p><strong>Data sources: </strong>COVID-NMA living systematic review (covid-nma.com), PubPeer, medRxiv, Research Square, SSRN.</p><p><strong>Methods: </strong>We considered randomised controlled trials (RCTs) in COVID-NMA that evaluated pharmacological treatments for COVID-19 and retrieved systematic reviewers' assessments of the risk of bias and outcome reporting bias. We also searched for commentary data on PubPeer and preprint servers up to 6 November 2023. We employed qualitative content analysis to develop themes and domains of methodological and reporting issues identified by commenters.</p><p><strong>Results: </strong>We identified 500 eligible RCTs. Systematic reviewers identified methodological and reporting issues in 446 (89%) RCTs. In 391 (78%) RCTs, the issues could be easily resolved by the trial authors; issues included incomplete reporting (49%), selection of the reported results (52%) and no access to the pre-specified plan (25%). Alternatively, 74 (15%) RCTs had received at least one comment on PubPeer or preprint servers, totalling 348 comments. In 46 (9%) RCTs, the issues identified by post-preprint and post-publication peer review comments could be easily resolved by the trial authors; the issues were related to incomplete reporting (6%), errors (5%), statistical analysis (3%), inconsistent reporting of methods and analyses (2%), spin (2%), selection of the reported results (1%) and no access to the raw data/pre-specified plan (1%).</p><p><strong>Conclusions: </strong>Without changing their process, systematic reviewers identified issues in most RCTs that could be easily resolved by the trial authors; however, the lack of an established author feedback mechanism represents a wasted opportunity for facilitating improvement and enhancing the overall manuscript quality. On the other hand, despite the existing feedback loop to authors present in post-publication peer review, it demonstrated limited effectiveness in identifying methodological and reporting issues.</p>\",\"PeriodicalId\":9059,\"journal\":{\"name\":\"BMJ Evidence-Based Medicine\",\"volume\":\" \",\"pages\":\"233-240\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320597/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Evidence-Based Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjebm-2024-113068\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Evidence-Based Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjebm-2024-113068","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:我们旨在确定系统审稿人以及预印本后和出版后同行评议在多大程度上确定了作者可以轻松解决的COVID-19试验中的方法学和报告问题。设计:定性研究。数据来源:COVID-NMA生活系统评价(covid-nma.com)、PubPeer、medRxiv、Research Square、SSRN。方法:我们考虑了评估COVID-19药物治疗的COVID-NMA随机对照试验(RCTs),并检索了系统评论者对偏倚风险和结果报告偏倚的评估。我们还搜索了截至2023年11月6日的PubPeer和预印本服务器上的评论数据。我们采用定性的内容分析来发展由评论者确定的方法和报告问题的主题和领域。结果:我们确定了500个符合条件的随机对照试验。系统审稿人在446项(89%)随机对照试验中发现了方法学和报告问题。在391项(78%)随机对照试验中,这些问题可以由试验作者轻松解决;问题包括报告不完整(49%),报告结果的选择(52%)和无法获得预先指定的计划(25%)。另外,74项(15%)随机对照试验在PubPeer或预印本服务器上至少收到了一条评论,共计348条评论。在46项(9%)随机对照试验中,通过预印本后和发表后同行评议发现的问题可以由试验作者轻松解决;这些问题与报告不完整(6%)、错误(5%)、统计分析(3%)、方法和分析报告不一致(2%)、spin(2%)、报告结果的选择(1%)以及无法访问原始数据/预先指定的计划(1%)有关。结论:在不改变流程的情况下,系统审稿人在大多数随机对照试验中发现了试验作者可以轻松解决的问题;然而,缺乏成熟的作者反馈机制意味着浪费了促进改进和提高整体稿件质量的机会。另一方面,尽管在发表后的同行评议中存在对作者的反馈循环,但它在识别方法和报告问题方面的有效性有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Post-publication peer review and the identification of methodological and reporting issues in COVID-19 trials: a qualitative study.

Objectives: We aimed to determine to what extent systematic reviewers and post-preprint and post-publication peer review identified methodological and reporting issues in COVID-19 trials that could be easily resolved by the authors.

Design: Qualitative study.

Data sources: COVID-NMA living systematic review (covid-nma.com), PubPeer, medRxiv, Research Square, SSRN.

Methods: We considered randomised controlled trials (RCTs) in COVID-NMA that evaluated pharmacological treatments for COVID-19 and retrieved systematic reviewers' assessments of the risk of bias and outcome reporting bias. We also searched for commentary data on PubPeer and preprint servers up to 6 November 2023. We employed qualitative content analysis to develop themes and domains of methodological and reporting issues identified by commenters.

Results: We identified 500 eligible RCTs. Systematic reviewers identified methodological and reporting issues in 446 (89%) RCTs. In 391 (78%) RCTs, the issues could be easily resolved by the trial authors; issues included incomplete reporting (49%), selection of the reported results (52%) and no access to the pre-specified plan (25%). Alternatively, 74 (15%) RCTs had received at least one comment on PubPeer or preprint servers, totalling 348 comments. In 46 (9%) RCTs, the issues identified by post-preprint and post-publication peer review comments could be easily resolved by the trial authors; the issues were related to incomplete reporting (6%), errors (5%), statistical analysis (3%), inconsistent reporting of methods and analyses (2%), spin (2%), selection of the reported results (1%) and no access to the raw data/pre-specified plan (1%).

Conclusions: Without changing their process, systematic reviewers identified issues in most RCTs that could be easily resolved by the trial authors; however, the lack of an established author feedback mechanism represents a wasted opportunity for facilitating improvement and enhancing the overall manuscript quality. On the other hand, despite the existing feedback loop to authors present in post-publication peer review, it demonstrated limited effectiveness in identifying methodological and reporting issues.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Evidence-Based Medicine
BMJ Evidence-Based Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
8.90
自引率
3.40%
发文量
48
期刊介绍: BMJ Evidence-Based Medicine (BMJ EBM) publishes original evidence-based research, insights and opinions on what matters for health care. We focus on the tools, methods, and concepts that are basic and central to practising evidence-based medicine and deliver relevant, trustworthy and impactful evidence. BMJ EBM is a Plan S compliant Transformative Journal and adheres to the highest possible industry standards for editorial policies and publication ethics.
期刊最新文献
Impact of prompt engineering on large language models for risk of bias assessment: a comparative study. Educating health professionals in evidence-based practice in 2026. Evaluating data extraction error by a large language model from randomised controlled trials: a large-scale empirical study. Equity and representativeness in pragmatic drug trials: methodological and ethical considerations. Correspondence on 'Effectiveness and clinical relevance of kinesio taping in musculoskeletal disorders: an overview of systematic reviews and evidence mapping' by Mo et al.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1